Does Blue Cross Blue Shield of North Carolina Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) approved by the FDA for stroke prevention in nonvalvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and VTE prophylaxis following hip or knee replacement surgery. Because patients take it daily, often indefinitely, the difference between a Tier 2 and Tier 4 copay can add up to more than $1,800 per year out of pocket.

The Clinical Case for Eliquis

The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced stroke or systemic embolism by 21% relative to warfarin (hazard ratio 0.79; 95% CI 0.66 to 0.94; P<0.001 for superiority) while also reducing major bleeding by 31% 1. Those numbers established apixaban as a first-line agent in the 2023 ACC/AHA Atrial Fibrillation Guideline, which carries a Class I recommendation for DOACs over warfarin in eligible patients with NVAF 2.

The AMPLIFY trial (N=5,395) similarly showed apixaban was noninferior to enoxaparin/warfarin for acute VTE treatment and produced 69% less major bleeding 3. These trial results inform why clinicians push back hard on insurer denials: switching a stable patient off apixaban for cost reasons carries real risk.

FDA-Approved Indications Covered by Most Plans

The FDA approved Eliquis in December 2012 for NVAF, and extended indications followed through 2014 4. BCBSNC generally covers all four FDA-approved indications, but the plan may require documentation showing the patient meets the specific indication criteria before approving the PA.

How BCBSNC Places Eliquis on Its Formulary

Tier Structure Across Plan Types

BCBSNC uses a tiered formulary that typically spans five levels. Tier 1 covers generics at the lowest cost; Tier 5 covers specialty drugs at the highest. Eliquis has historically landed at Tier 3 (preferred brand) on most BCBSNC commercial plans, meaning a 30-day supply costs roughly $47, $90 after deductible is met. Some plans moved Eliquis to Tier 4 (non-preferred brand) after 2022 contract changes, pushing copays above $100, $200 per fill 5.

With the 2024 launch of generic apixaban, certain BCBSNC formularies now list the generic on Tier 1 or Tier 2 and require a step-through to generic before approving brand Eliquis at the lower tier rate. Confirm your specific plan's drug list at the BCBSNC online pharmacy portal or call the member services number on the back of your insurance card.

Medicare Advantage and Part D Plans

BCBSNC Medicare Advantage plans follow CMS formulary rules. Under Medicare Part D, Eliquis falls into the protected drug class for anticoagulants, meaning CMS requires all Part D plans to cover all or substantially all anticoagulants 6. In practice, Eliquis appears on virtually every BCBSNC Medicare Advantage formulary, typically as Tier 3 with a standard 2025 copay of $42, $47 for a 30-day supply during the initial coverage phase. After crossing the catastrophic coverage threshold ($2,000 in 2025 under the Inflation Reduction Act changes), member cost drops to $0 7.

ACA Marketplace Plans

On BCBSNC ACA plans (Blue Value, Blue Local, Blue Select), Eliquis coverage and tier placement vary by metal level. Bronze plans often require meeting the full deductible (sometimes $7,000+) before copays apply, making a month's supply cost the full negotiated rate until the deductible is satisfied. Silver and Gold plans typically show lower effective costs after the deductible 8.

Prior Authorization Requirements for Eliquis at BCBSNC

What Triggers a PA Request

BCBSNC requires prior authorization for Eliquis on most commercial PPO and HMO plans. The PA is triggered at the pharmacy when the claim is submitted. Your pharmacist will tell you the claim is "pending PA," at which point your prescribing physician must submit documentation to BCBSNC 9.

Typical documentation the PA form requests includes:

• Confirmed diagnosis (ICD-10 code for NVAF, DVT, PE, or post-surgical VTE)
• CHA2DS2-VASc score if the indication is NVAF (score of 2 or greater in men, 3 or greater in women qualifies under AHA/ACC guidelines) 10
• For VTE indication: imaging or lab confirmation of clot
• Notation of contraindication, intolerance, or prior failure with warfarin if a step-therapy requirement exists

Step-Therapy Policies

Some BCBSNC plans include a step-therapy requirement stating the patient must first try warfarin (or in some cases rivaroxaban, which may be on a preferred tier) before Eliquis is covered. North Carolina passed step-therapy reform legislation (S.L. 2019-199), which requires that insured patients be granted a step-therapy override when there is a clinical reason the preferred drug is contraindicated, will cause an adverse reaction, or the patient previously tried and failed it 11. A physician letter documenting any of these conditions should accompany the PA request.

PA Approval Timelines

Federal rules under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) require health plans regulated by CMS to respond to standard PA requests within 7 calendar days and to urgent requests within 72 hours 12. For state-regulated commercial plans in North Carolina, the state's utilization review statute (N.C.G.S. § 58-50-61) mirrors these timelines. In practice, BCBSNC typically approves or denies within 3 to 5 business days for standard requests.

What to Do If BCBSNC Denies Your Eliquis Claim

First-Level Internal Appeal

If BCBSNC denies the PA, you have the right to an internal appeal. Request the denial letter in writing. It must include the specific clinical criteria used to deny the claim 13. Your physician should submit a peer-to-peer review request, which allows direct conversation with the BCBSNC medical reviewer. Studies published in JAMA Network Open found that peer-to-peer reviews overturn PA denials at significantly higher rates than written appeals alone 14.

External Independent Review

If the internal appeal is denied, North Carolina insureds can request an external independent review through the NC Department of Insurance. The reviewer is a board-certified specialist independent of BCBSNC. Under ACA provisions, the plan must abide by the external reviewer's decision 15.

Letters of Medical Necessity

A strong letter of medical necessity from your cardiologist or hematologist citing ARISTOTLE trial data, the 2023 ACC/AHA Class I DOAC recommendation, and the patient's specific bleeding risk on warfarin substantially improves appeal outcomes. The 2023 ACC/AHA guideline states: "In patients with AF at increased risk of stroke, antithrombotic therapy with a DOAC is recommended in preference to VKA therapy for most patients" 2.

The table below outlines a three-step appeal escalation framework clinicians can use when BCBSNC denies Eliquis:

| Step | Action | Timeline | Key Document | |------|--------|----------|--------------| | 1 | Peer-to-peer review with BCBSNC medical reviewer | Within 5 business days of denial | Physician attestation of indication and risk | | 2 | Formal written internal appeal with letter of medical necessity | 30 days from denial notice | ARISTOTLE/AMPLIFY citations, CHA2DS2-VASc score, step-therapy override documentation | | 3 | NC DOI external independent review | 4 months from denial or 60 days from internal denial | All prior correspondence plus specialist letter |

How Much Does Eliquis Cost at BCBSNC With and Without Coverage?

With Active BCBSNC Coverage

• Tier 3 commercial (deductible met): $47, $90 per 30-day supply
• Tier 4 commercial (deductible met): $100, $200+ per 30-day supply
• Medicare Advantage (initial coverage phase): $42, $47 per 30-day supply
• Medicare Advantage (catastrophic phase, 2025): $0

Without Coverage or Before Deductible

The retail cash price for a 30-day supply of Eliquis 5 mg twice daily ranges from approximately $530 to $620 at major North Carolina pharmacies based on GoodRx pricing data 16. Generic apixaban launched in 2024 after patent expiration and is now available at some pharmacies for $30, $80 per month cash price, which makes the generic a practical bridge while a PA is pending.

Manufacturer Copay Assistance

Bristol Myers Squibb and Pfizer offer the Eliquis $10 Co-pay Card for commercially insured, non-government-plan patients. Eligible patients pay no more than $10 for a 30-day supply. Patients covered by Medicare, Medicaid, or any federally funded program do not qualify for this card 17. The card is renewable annually and can be combined with BCBSNC commercial coverage.

Patient Assistance Programs

For uninsured or underinsured patients who do not qualify for the copay card, the Bristol Myers Squibb Patient Assistance Foundation provides Eliquis at no cost to eligible low-income patients. Income thresholds and application instructions are available at the BMS Foundation website. The NeedyMeds database also tracks state-level assistance programs for anticoagulants 18.

Switching to Generic Apixaban Under BCBSNC

Generic apixaban received FDA approval and entered the US market in 2024 following the resolution of patent litigation. Several BCBSNC formularies moved quickly to prefer the generic, placing it at Tier 1 or Tier 2 while shifting brand Eliquis to a higher tier 19. The FDA considers approved generic apixaban therapeutically equivalent to brand Eliquis under the Orange Book AB rating, meaning substitution is clinically acceptable for most patients 20.

Patients already stable on brand Eliquis should ask their pharmacist and cardiologist whether switching to generic is appropriate. From a pharmacokinetic standpoint, apixaban's bioavailability is approximately 50%, half-life is 12 hours, and it is primarily eliminated via fecal excretion with CYP3A4 involvement 21. No pharmacokinetic differences exist between bioequivalent generics and the brand in regulatory terms, but patients with complex comorbidities or polypharmacy may benefit from a prescriber review before switching.

Specific BCBSNC Plans and Eliquis: What to Check

Blue Options PPO and Blue Select

These commercial plans are the most common BCBSNC products for employer groups in North Carolina. Eliquis appears on both formularies, typically Tier 3. PA is required. Members can use the BCBSNC Find a Drug tool to confirm current tier placement before their plan year begins.

State Health Plan (SHBP) for NC State Employees

The North Carolina State Health Plan (SHBP), administered by BCBSNC, covers state employees and teachers. The SHBP formulary is separate from commercial products. Eliquis has been placed at Tier 3 on the SHBP Enhanced 80/20 Plan in recent benefit years, with a $55 copay per 30-day supply after the deductible 22. PA requirements mirror the commercial PA criteria. State employees should confirm current tier placement at the SHBP member portal each open enrollment period.

Blue Medicare Advantage Rx Plans

BCBSNC Blue Medicare Advantage plans follow CMS Part D rules. As noted above, anticoagulants including apixaban are a protected drug class under CMS policy 6. Coverage must be provided; the question for Medicare members is which tier and what copay. For 2025, the Inflation Reduction Act cap of $2,000 in annual Part D out-of-pocket costs benefits patients who take high-cost medications like Eliquis year-round 7.

Drug Interactions and Clinical Considerations That Affect PA Documentation

When submitting a PA, clinical documentation of drug interactions or contraindications to alternative anticoagulants strengthens the case for Eliquis specifically. Relevant pharmacological facts your physician should document:

Apixaban carries a dual P-gp and CYP3A4 interaction profile. Combined P-gp and strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, or ritonavir) increase apixaban exposure and may require dose reduction or avoidance 23. Combined P-gp and strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) reduce apixaban plasma concentrations significantly, potentially rendering it ineffective 24. These interactions are documented in the FDA label and support individualized drug selection.

For patients with end-stage renal disease (ESRD) on hemodialysis, the FDA label was updated to include a dosing recommendation based on clinical data 4. Warfarin's notoriously difficult management in ESRD patients, documented in multiple registry studies, provides further clinical rationale for preferring apixaban in this subgroup 25.

Verifying Your Coverage: A Step-by-Step Checklist

1. Log in to your BCBSNC member portal at bcbsnc.com and manage to "Drug Coverage" or "Find a Drug."
2. Enter "apixaban" or "Eliquis" and your current plan year.
3. Note the tier, any PA requirements, and whether quantity limits apply (BCBSNC commonly limits to a 30-day supply without a 90-day mail-order option enabled).
4. If PA is required, ask your prescribing physician's office to submit the PA simultaneously with the prescription to avoid dispensing delays.
5. If your plan requires step therapy, obtain documentation of any prior warfarin use, intolerance, or contraindication now rather than after a denial.
6. Download the Eliquis $10 copay card if you are commercially insured and not on a government program.
7. Ask the pharmacist to price both brand Eliquis and generic apixaban to identify the lower-cost option under your specific plan.
8. Set a calendar reminder 60 days before your plan year ends to re-verify tier placement, since formularies change annually.